PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina

Purpose PALB2 variants have been scarcely described in Argentinian and Latin-American reports. In this study, we describe molecular and clinical characteristics of PALB2 mutations found in multi-gene panels (MP) from breast-ovarian cancer (BOC) families in different institutions from Argentina. Meth...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2022-07, Vol.194 (2), p.403-412
Main Authors: Gonzalez, Ariana, Del Greco, Franco, Vargas-Roig, Laura, Brun, Bianca, Tabares, Gonzalo, Mampel, Alejandra, Montes, Cecilia, Martin, Claudia, Lopez, Marcela, Rossi, Norma, Bruno, Luisina, Ponce, Carolina, Quaglio, Patricia, Yanzi, Alvaro, Acevedo, Santiago, Lugo, Lilia, Lopez Breccia, Paula, Avila, Silvia, Sisterna, Silvina, Del Castillo, María Soledad, Vazquez, Martín, Nuñez, Lina M.
Format: Article
Language:English
Subjects:
Breast cancer
Cancer
Cancer research
Care and treatment
Epidemiology
Family
Gene mutations
Genes
Genetic aspects
Invasiveness
Medicine
Medicine & Public Health
Mutation
Oncology
Ovarian cancer
Patients
Phenotypes
Political aspects
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose PALB2 variants have been scarcely described in Argentinian and Latin-American reports. In this study, we describe molecular and clinical characteristics of PALB2 mutations found in multi-gene panels (MP) from breast-ovarian cancer (BOC) families in different institutions from Argentina. Methods We retrospectively identified PALB2 pathogenic (PV) and likely pathogenic (LPV) variants from a cohort of 1905 MP results, provided by one local lab (Heritas) and SITHER (Hereditary Tumor Information System) public database. All patients met hereditary BOC clinical criteria for testing, according to current guidelines. Results The frequency of PALB2 mutations is 2.78% (53/1905). Forty-eight (90.5%) are PV and five (9.5%) are LPV. Most of the 18 different mutations (89%) are nonsense and frameshift types and 2 variants are novel. One high-rate recurrent PV (Y551*) is present in 43% (23/53) of the unrelated index cases. From the 53 affected carriers, 94% have BC diagnosis with 14% of bilateral cases. BC phenotype is mainly invasive ductal (78%) with 62% of hormone-receptor positive and 22% of triple negative tumors. Self-reported ethnic background of the cohort is West European (66%) and native Latin-American (20%) which is representative of Buenos Aires and other big urban areas of the country. Conclusion This is the first report describing molecular and clinical characteristics of PALB2 carriers in Argentina. Frequency of PALB2 PV in Argentinian HBOC families is higher than in other reported populations. Y551* is a recurrent mutation that seems to be responsible for almost 50% of PALB2 cases.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-022-06620-5